(-)-epigallocatechin 3-gallate/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“As indicated in Figure 1, EGCG treatment reduced body weight by 10% and gonadal WAT (gWAT) mass by 20%.”
Quoted verbatim from Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.. - Study
- animal · not in humans
- Duration
- 14 days
- Dose
- 20 mg/kg/day by oral gavage for 2 weeks
- Population
- Male C57BL/6 mice fed a high-fat diet for 8 weeks, then treated with EGCG or vehicle for 2 weeks under continued high-fat diet
Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.2020PMID:33050029Permalink
Keep reading
- Everything the graph holds on (-)-epigallocatechin 3-gallate
- Every compound studied against Body mass
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M454XHDDV59BSSVD4KTWJYKD